ECSP003508A - Formas polimorfas de un citrato de azobiciclo [2.2.2] octan-3-amina y sus composiciones farmaceuticas - Google Patents
Formas polimorfas de un citrato de azobiciclo [2.2.2] octan-3-amina y sus composiciones farmaceuticasInfo
- Publication number
- ECSP003508A ECSP003508A EC2000003508A ECSP003508A ECSP003508A EC SP003508 A ECSP003508 A EC SP003508A EC 2000003508 A EC2000003508 A EC 2000003508A EC SP003508 A ECSP003508 A EC SP003508A EC SP003508 A ECSP003508 A EC SP003508A
- Authority
- EC
- Ecuador
- Prior art keywords
- citrate
- octan
- azobiciclo
- amina
- pharmaceutical compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 title abstract 2
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 abstract 2
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- JASMWYNKLTULAN-UHFFFAOYSA-N octan-3-amine Chemical compound CCCCCC(N)CC JASMWYNKLTULAN-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una forma polimorfa cristalina individual del citrato de (2S,3S) -(metoxi-5-t-buti!fenilmetil-2-difenilmetil-I-azobiciclo[2,2,2) octan-3-amina (citrato monohidrato) y su composición farmacéutica. La composición farmacéutica de la forma polimorfa si el citrato monohidrato tiene la estabilidad necesaria para una formulación para tratar la emesis. La administración de esta composición farmacéutica es una forma de dosificación oral de liberación inmediata, preferiblemente en forma de comprimido o cápsula, o intravenosa.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13699299P | 1999-06-01 | 1999-06-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP003508A true ECSP003508A (es) | 2002-02-25 |
Family
ID=22475338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2000003508A ECSP003508A (es) | 1999-06-01 | 2000-06-01 | Formas polimorfas de un citrato de azobiciclo [2.2.2] octan-3-amina y sus composiciones farmaceuticas |
Country Status (48)
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0507301A (pt) * | 2004-01-30 | 2007-06-26 | Pfizer Prod Inc | composições farmacêuticas de antagonistas do receptor de nuerocinina e ciclodextrina e métodos para melhor toleráncia no local de injeção |
CN101090735A (zh) * | 2004-01-30 | 2007-12-19 | 辉瑞产品有限公司 | 用于使用液体剂型用β-环糊精制备多剂量制剂的抗菌防腐剂 |
MXPA06007964A (es) | 2004-01-30 | 2007-01-26 | Pfizer Prod Inc | Antagonistas del receptor nk-1 para mejorar la recuperacion de anestesia. |
BRPI0507334A (pt) * | 2004-02-02 | 2007-07-03 | Pfizer Prod Inc | processo para a preparação de -1(2s,3s)-2-benzidril-n-(5-terc-butil-2-metoxibenzila)q uinuclidin-3-amina |
EP2968152B2 (en) * | 2013-03-15 | 2022-06-22 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
CN110577522B (zh) * | 2018-06-07 | 2022-12-27 | 东莞市东阳光动物保健药品有限公司 | 马罗匹坦柠檬酸盐新晶型及其制备方法 |
CN112979639A (zh) * | 2019-12-16 | 2021-06-18 | 四川科瑞德凯华制药有限公司 | 一种马罗皮坦新晶型及其制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0733386B2 (ja) * | 1991-05-31 | 1995-04-12 | フアイザー・インコーポレイテツド | キヌクリジン誘導体 |
US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
US5576317A (en) * | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
-
2000
- 2000-05-08 US US09/566,307 patent/US6255320B1/en not_active Expired - Lifetime
- 2000-05-17 HN HN2000000077A patent/HN2000000077A/es unknown
- 2000-05-18 MX MXPA01012325A patent/MXPA01012325A/es unknown
- 2000-05-18 WO PCT/IB2000/000665 patent/WO2000073304A1/en active IP Right Grant
- 2000-05-18 AT AT00925528T patent/ATE244239T1/de not_active IP Right Cessation
- 2000-05-18 EE EEP200100656A patent/EE200100656A/xx unknown
- 2000-05-18 PT PT00925528T patent/PT1181290E/pt unknown
- 2000-05-18 HU HU0201301A patent/HUP0201301A3/hu unknown
- 2000-05-18 DE DE60003679T patent/DE60003679T2/de not_active Expired - Lifetime
- 2000-05-18 CN CNB008082782A patent/CN1146565C/zh not_active Expired - Lifetime
- 2000-05-18 JP JP2001500629A patent/JP3830816B2/ja not_active Expired - Lifetime
- 2000-05-18 IL IL14640600A patent/IL146406A0/xx not_active IP Right Cessation
- 2000-05-18 EA EA200101108A patent/EA003731B1/ru active Protection Beyond IP Right Term
- 2000-05-18 KR KR10-2001-7015494A patent/KR100476606B1/ko not_active Expired - Fee Related
- 2000-05-18 YU YU81101A patent/YU81101A/sh unknown
- 2000-05-18 OA OA1200100318A patent/OA11956A/en unknown
- 2000-05-18 BR BR0011094-9A patent/BR0011094A/pt not_active Application Discontinuation
- 2000-05-18 AU AU44248/00A patent/AU767334B2/en not_active Expired
- 2000-05-18 AP APAP/P/2001/002349A patent/AP2001002349A0/en unknown
- 2000-05-18 HR HR20010904A patent/HRP20010904A2/hr not_active Application Discontinuation
- 2000-05-18 PL PL00352716A patent/PL196046B1/pl not_active IP Right Cessation
- 2000-05-18 DK DK00925528T patent/DK1181290T3/da active
- 2000-05-18 EP EP00925528A patent/EP1181290B1/en not_active Expired - Lifetime
- 2000-05-18 ES ES00925528T patent/ES2199825T3/es not_active Expired - Lifetime
- 2000-05-18 NZ NZ515349A patent/NZ515349A/xx unknown
- 2000-05-18 CZ CZ20014269A patent/CZ295819B6/cs not_active IP Right Cessation
- 2000-05-18 TR TR2001/03473T patent/TR200103473T2/xx unknown
- 2000-05-18 SK SK1733-2001A patent/SK285820B6/sk not_active IP Right Cessation
- 2000-05-18 SI SI200030161T patent/SI1181290T1/xx unknown
- 2000-05-18 UA UA2001118214A patent/UA66925C2/uk unknown
- 2000-05-18 CA CA002372238A patent/CA2372238C/en not_active Expired - Lifetime
- 2000-05-23 PA PA20008496101A patent/PA8496101A1/es unknown
- 2000-05-26 CO CO00039195A patent/CO5170463A1/es not_active Application Discontinuation
- 2000-05-26 TW TW089110206A patent/TWI285204B/zh not_active IP Right Cessation
- 2000-05-29 UY UY26176A patent/UY26176A1/es not_active Application Discontinuation
- 2000-05-30 PE PE2000000520A patent/PE20010209A1/es not_active Application Discontinuation
- 2000-05-30 AR ARP000102663A patent/AR033331A1/es active IP Right Grant
- 2000-05-30 MY MYPI20002409A patent/MY133508A/en unknown
- 2000-05-31 GT GT200000087A patent/GT200000087A/es unknown
- 2000-05-31 TN TNTNSN00120A patent/TNSN00120A1/fr unknown
- 2000-05-31 MA MA25997A patent/MA26742A1/fr unknown
- 2000-05-31 DZ DZ000101A patent/DZ3050A1/xx active
- 2000-05-31 SV SV2000000093A patent/SV2001000093A/es unknown
- 2000-06-01 EC EC2000003508A patent/ECSP003508A/es unknown
-
2001
- 2001-11-28 ZA ZA200109775A patent/ZA200109775B/en unknown
- 2001-11-30 NO NO20015848A patent/NO20015848L/no not_active Application Discontinuation
- 2001-12-10 BG BG106204A patent/BG65240B1/bg unknown
-
2007
- 2007-03-27 CY CY2007011C patent/CY2007011I1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR036768A1 (es) | Formas de administracion de propiverina o sus sales farmaceuticamente aceptables con liberacion prolongada de la sustancia activa | |
CL2009001682A1 (es) | Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00). | |
AR022008A1 (es) | Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento | |
ES2181055T3 (es) | Formulaciones galenicas que contienen antagonistas de opiaceos. | |
DK0954314T3 (da) | Doseringsformer til bedring af mandlig erektionsdefekt | |
BR0206695A (pt) | Formas de dosagem de epotilonas para administração oral | |
NO330947B1 (no) | Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand | |
EA200901393A1 (ru) | Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат | |
ECSP066318A (es) | Composición para la liberación de una base debil por un periodo extendido de tiempo | |
AP2003002763A0 (en) | Controlled release formulations for oral administration | |
AR001765A1 (es) | Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales | |
ECSP003508A (es) | Formas polimorfas de un citrato de azobiciclo [2.2.2] octan-3-amina y sus composiciones farmaceuticas | |
ECSP003538A (es) | Polimorfos de un diclorhidrato cristalino de azobiciclo [2.2.2.] oct-3-ilamina y sus composiciones farmaceuticas | |
UY26177A1 (es) | Polimorfos de un citrato de azobiciclo (2.2.2) oct-3- ilamina cristalino y sus composiciones farmacéuticas. | |
HUP0400495A2 (hu) | Apomorfin szájnyálkahártyán keresztül történő adagolására szolgáló orális készítmény | |
MY141008A (en) | Oral formulations of deoxypeganine and their uses | |
ATE302010T1 (de) | Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus | |
IT1293835B1 (it) | Composizioni farmaceutiche orali in forma solida a cessione modulata contenenti nicorandil e procedimento per la loro preparazione | |
ECSP003510A (es) | Polimorfos de un citrato de azobiciclo (2,2,2) oct - 3 - ilamina cristalino y sus composiciones farmaceuticas | |
GT200000104A (es) | Polimorfos de un diclorhidrato cristalino de azobiciclo 2.2.2 oct - 3 - ilamina y sus composicionesfarmaceuticas. | |
ATE429905T1 (de) | Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung | |
MY145885A (en) | Controlled release formulations for oral administration | |
UY27771A1 (es) | Procedimiento para preparar composiciones farmacéuticas de 2 a 8 mg de 5- (4-(2-(n-metil.n(2-piridilo) amino) etoxi) bencilo) tiazolidino-2,4-diona. | |
PE20090292A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante |